This report includes defined and up to date development strategies for 175 leukemia drugs (>250
projects) within the portfolio of 126 investigators, from Preclinical to Marketed. Leukemia drugs are
further dived into the sub-indications of ALL, AML, CLL, CML, HCL and MCL. The report is written for
you to understand and assess the impact of competitor entry and corresponding changes to
development strategies for your own portfolio products. It serves as an external commercial
advocate for pharmaceutical companies’ portfolio planning and new product planning by:
Providing competitive input to the R&D organization to guide development of early product
ideas and ensure efforts are aligned with business objectives
Analyzing, correlating and integrating valuable data sources in order to provide accurate data
for valuation of pipeline, in-licensing and new business opportunities
Providing commercial analytic support for due diligence on in-licensing and acquisition opportunities
This report will also be an important part of creating and implementing a market development plan
for any leukemia drugs to ensure that the optimal market conditions exist by the time the product is
commercialized.
BioSeeker’s leukemia pipeline evaluation of development options, competitive landscape and
positioning is derived through extensive pipeline benchmarking analysis, including:
Single Drug Target Analysis of 136 Drug Targets
Highlighting twelve themes about the drug target (i.e. Drugs and investigators sharing a
particular target, Types of compounds aimed at a specific target, Protein-protein interactions
of a specific target with other known leukemia drug targets, Pathway involvement of a drug
target, Presence of structural and protein expression data of a target etc.)
Supportive chapters on selected drug themes above
Competitive Landscape Analysis based on 115 Identified Drug Target Combinations
Identifies New and Unique leukemia drugs by developmental stage
Head-to-head targeting competition
Targeting competition by at least 50% bi-directional drug target combination match
Clinical validation and progress on all identified drug target combinations
Competitive Landscape Analysis based on Compound Strategies at Work
Identifies New and Unique leukemia drugs based on six different compound strategies (Small
(0 items)
